Saama, iNDX.Ai launch COVID-19 Command Center analytics platform

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/Eugeneonline)
(Image: Getty/Eugeneonline)

Related tags: COVID-19, Coronavirus, Saama Technologies, data analysis

The technology offers data analytics capabilities specific to the research and development of therapies targeted at the virus.

The COVID-19 Command Center analytics platform combines Saama Technologies’ Life Science Analytic Cloud (LSAC) and iNDC.Ai’s iCore clinical analytics platforms. The solution is intended to help various life-science companies accelerate internal R&D programs for creating treatments and preventatives for the virus behind the pandemic.

Suresh Katta, founder and CEO of Saama Technologies, said the company is interested in ensuring companies across the industry have access to technology and information to help their research efforts.

Saama wants all life science companies, whether they are engaged in public or private research efforts, to have access to the best possible analytics platform so they can expedite promising COVID-19 clinical trials and bring critical vaccines and treatments to the market as soon as possible​,” he said. “The COVID-19 Command Center, the first offering from Saama’s purpose-built Command Center strategy, is customized to meet immediate needs related to research on the novel coronavirus, but can also be used more broadly for other infectious disease clinical development efforts now and in the future​.”

Last month, Saama Technologies announced the establishment of the EndPandemic National Data Consortium​; both it and iNDX.Ai are members. The collaborative group is intended to harness data pulled from COVID-19 trials to help speed the development and availability of therapies.

According to Saama Technologies, the aim of the COVID-19 Command Center is to give  sponsors conducting in-house COVID-19 clinical development access to an AI-powered data analytics platform. The platform includes patient data from ongoing COVID-19 clinical trials in China, South Korea, and the US, incorporating data from nearly 8,500 patients, including more than 3,000 positive cases.

The COVID-19 Command Center is engineered to provide the multiomics and clinical data analytics necessary to manage COVID-19 clinical studies. From preclinical development to approval, researchers will be able to optimize study design, patient selection, site activation and scientific analysis by dynamically visualizing, analyzing, and interrogating data efficiently.  

Mohan Uttarwar, CEO of iNDX.Ai, said his company believes that AI-empowered data analytics will be useful in accelerating clinical research in trials to help deliver potential COVID-19 treatments.

The COVID-19 Command Center ensures that every life science company, whether engaged in solo or collaborative research, will be able to apply state-of-the-art data analytics to inform and advance their research and help end the pandemic​,” he said. “By partnering on the COVID-19 Command Center, iNDX.Ai and Saama provide an end-to-end clinical development solution, from in silico biomarker discovery to Investigational new drug application submission​.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more